5520 Journal of Medicinal Chemistry, 2008, Vol. 51, No. 18
TahiroVic et al.
(12) Choi, Y. B.; Lipton, S. A. Identification and mechanism of action of
two histidine residues underlying high-affinity Zn2+ inhibition of the
NMDA receptor. Neuron 1999, 23, 171–180.
(13) Low, C. M.; Zheng, F.; Lyuboslavsky, P.; Traynelis, S. F. Molecular
determinants of coordinated proton and zinc inhibition of N-methyl-
D-aspartate NR1/NR2A receptors. Proc. Natl. Acad. Sci. U.S.A. 2000,
97, 11062–11067.
(14) Paoletti, P.P.-D., F.; Fayyazuddin, A.; Le Goff, A.; Callebaut, I.; Neyton,
J. Molecular organization of zinc binding N-terminal modulatory domain
in a NMDA receptor subunit. Neuron 2000, 28, 911–925.
(31) Connors, S. P.; Gill, E. W.; Terrar, D. A. Actions and Mechanisms of
Action of Novel Analogs of Sotalol on Guinea Pig and Rabbit
Ventricular Cells. Br. j. Pharmacol. 1992, 106, 958–965.
(32) Ilyin, V. I.; Whittemore, E. R.; Guastella, J.; Weber, E.; Woodward,
R. M. Subtype-selective inhibition of N-methyl-D-aspartate receptors
by haloperidol. Mol. Pharmacol. 1996, 50, 1541–1550.
(33) Kew, J. N.; Trube, G.; Kemp, J. A. A novel mechanism of activity-
dependent NMDA receptor antagonism describes the effect of ifen-
prodil in rat cultured cortical neurones. J. Physiol. (London) 1996,
497, 761–772.
(34) Kew, J. N. C.; Trube, G.; Kemp, J. A. State-dependent NMDA receptor
antagonism by Ro 8-4304, a novel NR2B selective, non-competitive,
voltage-independent antagonist. Br. J. Pharmacol. 1998, 123, 463–
472.
(35) Masuko, T.; Kashiwagi, K.; Kuno, T.; Nguyen, N. D.; Pahk, A. J.;
Fukuchi, J.; Igarashi, K.; Williams, K. A regulatory domain (R1-R2)
in the amino terminus of the N-methyl-D-aspartate receptor: Effects
of spermine, protons, and ifenprodil, and structural similarity to
bacterial leucine/isoleucine/valine binding protein. Mol. Pharmacol.
1999, 55, 957–969.
(36) Gallagher, M. J.; Huang, H.; Lynch, D. R. Modulation of the N-methyl-
D-aspartate receptor by haloperidol: NR2B-specific interactions. J. Neu-
rochem. 1998, 70, 2120–2128.
(37) Wong, E.; Ng, F. M.; Yu, C. Y.; Lim, P.; Lim, L. H.; Traynelis, S. F.;
Low, C. M. Expression and characterization of soluble amino-terminal
domain of NR2B subunit of N-methyl-D-aspartate receptor. Protein
Sci. 2005, 14, 2275–2283.
(38) Rachline, J.; Perin-Dureau, F.; Le Goff, A.; Neyton, J.; Paoletti, P.
The micromolar zinc-binding domain on the NMDA receptor subunit
NR2B. J. Neurosci. 2005, 25, 308–317.
(39) Pfeiffer, C. C. Optical Isomerism and Pharmacological Action, a
Generalization. Science 1956, 124, 29–31.
(40) Mesecar, A. D.; Koshland, D. E. A new model for protein stereospeci-
ficity. Nature 2000, 408, 668.
(41) Mezzetti, A.; Schrag, J. D.; Cheong, C. S.; Kazlauskas, R. J. Mirror-
image packing in enantiomer discrimination: Molecular basis for the
enantioselectivity of B-cepacia lipase toward 2-methyl-3-phenyl-1-
propanol. Chem. Biol. 2005, 12, 427–437.
(15) Perin-Dureau, F.; Rachline, J.; Neyton, J.; Paoletti, P. Mapping the
binding site of the neuroprotectant ifenprodil on NMDA receptors.
J. Neurosci. 2002, 22, 5955–5965.
(16) Williams, K. Ifenprodil Discriminates Subtypes of the N-Methyl-D-
Aspartate Receptor: Selectivity and Mechanisms at Recombinant
Heteromeric Receptors. Mol. Pharmacol. 1993, 44, 851–859.
(17) Scatton, B.; Avenet, P.; Benavides, J.; Carter, C.; Duverger, D.; Oblin,
A.; Perrault, G.; Sanger, D. J.; Schoemaker, H. Neuroprotective
Potential of the Polyamine site-directed NMDA Receptor Antagonists:
Ifenprodil and Eliprodil. In Direct and Allosteric Control of Glutamate
Receptors; Palfreyman, M. G., Reynolds, I. J., Skolnick, P., Eds.; CRC
Press: Boca Raton, FL, 1994; p 139.
(18) Chenard, B. L.; Bordner, J.; Butler, T. W.; Chambers, L. K.; Collins,
M. A.; Decosta, D. L.; Ducat, M. F.; Dumont, M. L.; Fox, C. B.;
Mena, E. E.; Menniti, F. S.; Nielsen, J.; Pagnozzi, M. J.; Richter,
K. E. G.; Ronau, R. T.; Shalaby, I. A.; Stemple, J. Z.; White, W. F.
(1S,2S)-1-(4-Hydroxyphenyl)-2-(4-Hydroxy-4-Phenylpiperidino)-1-
Propanol: A Potent New Neuroprotectant Which Blocks N-Methyl-
D-Aspartate Responses. J. Med. Chem. 1995, 38, 3138–3145.
(19) Mott, D. D.; Doherty, J. J.; Zhang, S. N.; Washburn, M. S.; Fendley,
M. J.; Lyuboslavsky, P.; Traynelis, S. F.; Dingledine, R. Phenyletha-
nolamines inhibit NMDA receptors by enhancing proton inhibition.
Nat. Neurosci. 1998, 1, 659–667.
(20) Fischer, G.; Mutel, V.; Trube, G.; Malherbe, P.; Kew, J. N. C.;
Mohacsi, E.; Heitz, M. P.; Kemp, J. A. Ro 25-6981, a highly potent
and selective blocker of N-methyl-D-aspartate receptors containing the
NR2B subunit. Characterization in vitro. J. Pharmacol. Exp. Ther.
1997, 283, 1285–1292.
(42) Omega, version 2.0; Openeye Scientific Software, Inc.: Santa Fe, NM,
2006.
(43) Hawkins, P. C. D.; Skillman, A. G.; Nicholls, A. Comparison of Shape-
Matching and Docking as virtual Screening Tools. J. Med. Chem. 2007,
50, 74–82.
(44) EON, version 1.1; OpenEye Scientific Software, Inc.: Santa Fe, NM,
2006.
(45) Nicholls, A.; MacCuish, N. E.; MacCuish, J. D. Variable Selection
and Model Validation of 2D and 3D Molecular Descriptors. J. Com-
put.-Aided. Mol. Des. 2004, 18, 451–474.
(21) Barta-Szalai, G.; Borza, I.; Bozo, E.; Kiss, C.; Agai, B.; Proszenyak,
A.; Keseru, G. M.; Gere, A.; Kolok, S.; Galgoczy, K.; Horvath, C.;
Farkas, S.; Domany, G. Oxamides as novel NR2B selective NMDA
receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 3953–3956.
(22) McCauley, J. A.; Theberge, C. R.; Romano, J. J.; Billings, S. B.;
Anderson, K. D.; Claremon, D. A.; Freidinger, R. M.; Bednar, R. A.;
Mosser, S. D.; Gaul, S. L.; Connolly, T. M.; Condra, C. L.; Xia, M. H.;
Cunningham, M. E.; Bednar, B.; Stump, G. L.; Lynch, J. J.; Macaulay,
A.; Wafford, K. A.; Koblan, K. S.; Liverton, N. J. NR2B-selective
N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-sub-
stituted benzimidazoles. J. Med. Chem. 2004, 47, 2089–2096.
(23) Borza, I.; Kolok, S.; Gere, A.; Agai-Csongor, E.; Agai, B.; Tarkanyi,
G.; Horvath, C.; Barta-Szalai, G.; Bozo, E.; Kiss, C.; Bielik, A.; Nagy,
J.; Farkas, S.; Domany, G. Indole-2-carboxamides as novel NR2B
selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 2003,
13, 3859–3861.
(24) Curtis, N. R.; Diggle, H. J.; Kulagowski, J. J.; London, C.; Grimwood,
S.; Hutson, P. H.; Murray, F.; Richards, P.; Macaulay, A.; Wafford,
K. A. Novel N-1-(benzyl)cinnamamidine derived NR2B subtype-
selective NMDA receptor antagonists. Bioorg. Med. Chem. Lett. 2003,
13, 693–696.
(25) Wright, J. L.; Kesten, S. R.; Upasani, R. B. LanN. C. 4-Benzylpip-
eridinylalkylsulfinyl-substituted heterocycles and their use as subtype-
selective NMDA receptor antagonists. WO 2000000197, 2000.
(26) Tamiz, A. P.; Cai, S. X.; Zhou, Z. L.; Yuen, P. W.; Schelkun, R. M.;
Whittemore, E. R.; Weber, E.; Woodward, R. M.; Keana, J. F. W.
Structure-activity relationship of N-(phenylalkyl)cinnamides as novel
NR2B subtype-selective NMDA receptor antagonists. J. Med. Chem.
1999, 42, 3412–3420.
(27) Kitaori, K.; Furukawa, Y.; Yoshimoto, H.; Otera, J. CsF in organic
synthesis. Regioselective nucleophilic reactions of phenols with
oxiranes leading to enantiopure beta-blockers. Tetrahedron 1999, 55,
14381–14390.
(28) Sajiki, H.; Hattori, K.; Hirota, K. The formation of a novel Pd/C-
ethylenediamine complex catalyst: chemoselective hydrogenation
without deprotection of the O-benzyl and N-Cbz groups. J. Org. Chem.
1998, 63, 7990–7992.
(29) Sajiki, H.; Hattori, K.; Hirota, K. Highly chemoselective hydrogenation
with retention of the epoxide function using a heterogeneous Pd/C:
ethylenediamine catalyst and THF. Chem.sEur. J. 2000, 6, 2200–2204.
(30) Choi, W. B.; Wilson, L. J.; Yeola, S.; Liotta, D. C.; Schinazi, R. F. In
Situ Complexation Directs the Stereochemistry of N-Glycosylation in
the Synthesis of Oxathiolanyl and Dioxolanyl Nucleoside Analogs.
J. Am. Chem. Soc. 1991, 113, 9377–9379.
(46) Nicholls, A.; Grant, J. A. Molecular shape and electrostatics in the
encoding of relevant chemical information. J. Comput.-Aided. Mol.
Des. 2005, 19, 661–686.
(47) Geballe, M.; Traynelis, S. F.; Snyder, J. P. unpublished.
(48) McCauley, J. A.; Theberge, C. R.; Romano, J. J.; Billings, S. B.;
Anderson, K. D.; Claremon, D. A.; Freidinger, R. M.; Bednar, R. A.;
Mosser, S. D.; Gaul, S. L.; Connolly, T. M.; Condra, C. L.; Xia, M. H.;
Cunningham, M. E.; Bednar, B.; Stump, G. L.; Lynch, J. J.; Macaulay,
A.; Wafford, K. A.; Koblan, K. S.; Liverton, N. J. NR2B-selective
N-Methyl-D-aspartate antagonists: synthesis and evaluation of 5-sub-
stituted benzimidazoles. J. Med. Chem. 2004, 47, 2089–2096.
(49) Whetsell, W. O. Current concepts of excitotoxicity. J. Neuropath. Exp.
Neur. 1996, 55, 1–13.
(50) Dirnagl, U.; Iadecola, C.; Moskowitz, M. A. Pathobiology of ischaemic
stroke: an integrated view. Trends Neurosci. 1999, 22, 391–397.
(51) Brauner-Osborne, H.; Egebjerg, J.; Nielsen, E. O.; Madsen, U.;
Krogsgaard-Larsen, P. Ligands for glutamate receptors: design and
therapeutic prospects. J. Med. Chem. 2000, 43, 2609–2645.
(52) Choi, D. W.; Mauluccigedde, M.; Kriegstein, A. R. Glutamate
Neurotoxicity in Cortical Cell Culture. J. Neurosci. 1987, 7, 357–
368.
(53) Koh, J. Y.; Choi, D. W. Quantitative Determination of Glutamate
Mediated Cortical Neuronal Injury in Cell Culture by Lactate-
Dehydrogenase Efflux Assay. J. Neurosci. Methods 1987, 20, 83–90.
(54) Park, C. K.; Nehls, D. G.; Graham, D. I.; Teasdale, G. M.; Mcculloch,
J. The Glutamate Antagonist MK-801 Reduces Focal Ischemic Brain
Damage in the Rat. Ann. Neurol. 1988, 24, 543–551.
(55) Miyabe, M.; Kirsch, J. R.; Nishikawa, T.; Koehler, R. C.; Traystman,
R. J. Comparative analysis of brain protection by N-methyl-D-aspartate
receptor antagonists after transient focal ischemia in cats. Crit. Care
Med. 1997, 25, 1037–1043.
(56) Dogan, A.; Rao, A. M.; Baskaya, M. K.; Rao, V. L. R.; Rastl, J.;
Donaldson, D.; Dempsey, R. J. Effects of ifenprodil, a polyamine site
NMDA receptor antagonist on reperfusion injury after transient focal
cerebral ischemia. J. Neurosurg. 1997, 87, 921–926.